Natalie E Parks1, Gaurav Goyal1, Ronald S Go1, Jay Mandrekar1, W Oliver Tobin1. 1. Departments of Neurology (NEP, WOT), Hematology (GG, RSG), and Biomedical Statistics and Informatics (JM), Mayo Clinic, Rochester, MN; and Division of Neurology (NEP), Dalhousie University, Halifax, Canada.
Abstract
BACKGROUND: We describe the neuroradiologic features of a cohort of patients with Erdheim-Chester disease. METHODS: We assessed patients at Mayo Clinic Rochester between January 1, 1990, and July 31, 2016, with pathologically confirmed Erdheim-Chester disease (n = 53). RESULTS: Neuroimaging, including head CT (n = 17), brain MRI (n = 39), orbital MRI (n = 15), and spine MRI (n = 16), was available for 42 participants. Median age at diagnosis was 55 years (interquartile range 46-66) with higher male prevalence (33:20). Neurologic symptoms were identified in 47% (25/53); BRAFV600E mutation in 58% (15/26). Median follow-up was 2 years (range 0-20) with 18 patients deceased. Radiologic disease evidence was seen in dura (6/41), brainstem (9/39), cerebellum (8/39), spinal cord (2/16), spinal epidura (2/16), hypothalamic-pituitary axis (17/39), and orbits (13/42). T2 white matter abnormalities (Fazekas score ≥1) were present in 21/34 patients. Diabetes insipidus was present in 30% (16/53); 8 had abnormal hypothalamic-pituitary axis imaging. Radiographic evidence of CNS involvement (i.e., dural, brain, including Fazekas score >1, or spinal cord) occurred in 55% (22/40) and was unassociated with significantly increased mortality. CONCLUSIONS: Erdheim-Chester disease commonly and variably involves the neuraxis. Patients with suspected Erdheim-Chester disease should undergo MRI brain and spine and screening investigations (serum sodium, serum and urine osmolality) for diabetes insipidus to clarify extent of neurologic disease.
BACKGROUND: We describe the neuroradiologic features of a cohort of patients with Erdheim-Chester disease. METHODS: We assessed patients at Mayo Clinic Rochester between January 1, 1990, and July 31, 2016, with pathologically confirmed Erdheim-Chester disease (n = 53). RESULTS: Neuroimaging, including head CT (n = 17), brain MRI (n = 39), orbital MRI (n = 15), and spine MRI (n = 16), was available for 42 participants. Median age at diagnosis was 55 years (interquartile range 46-66) with higher male prevalence (33:20). Neurologic symptoms were identified in 47% (25/53); BRAFV600E mutation in 58% (15/26). Median follow-up was 2 years (range 0-20) with 18 patients deceased. Radiologic disease evidence was seen in dura (6/41), brainstem (9/39), cerebellum (8/39), spinal cord (2/16), spinal epidura (2/16), hypothalamic-pituitary axis (17/39), and orbits (13/42). T2 white matter abnormalities (Fazekas score ≥1) were present in 21/34 patients. Diabetes insipidus was present in 30% (16/53); 8 had abnormal hypothalamic-pituitary axis imaging. Radiographic evidence of CNS involvement (i.e., dural, brain, including Fazekas score >1, or spinal cord) occurred in 55% (22/40) and was unassociated with significantly increased mortality. CONCLUSIONS: Erdheim-Chester disease commonly and variably involves the neuraxis. Patients with suspected Erdheim-Chester disease should undergo MRI brain and spine and screening investigations (serum sodium, serum and urine osmolality) for diabetes insipidus to clarify extent of neurologic disease.
Authors: P Sedrak; L Ketonen; P Hou; N Guha-Thakurta; M D Williams; R Kurzrock; J M Debnam Journal: AJNR Am J Neuroradiol Date: 2011-09-29 Impact factor: 3.825
Authors: Eli L Diamond; Lorenzo Dagna; David M Hyman; Giulio Cavalli; Filip Janku; Juvianee Estrada-Veras; Marina Ferrarini; Omar Abdel-Wahab; Mark L Heaney; Paul J Scheel; Nancy K Feeley; Elisabetta Ferrero; Kenneth L McClain; Augusto Vaglio; Thomas Colby; Laurent Arnaud; Julien Haroche Journal: Blood Date: 2014-05-21 Impact factor: 22.113
Authors: Jean-François Emile; Oussama Abla; Sylvie Fraitag; Annacarin Horne; Julien Haroche; Jean Donadieu; Luis Requena-Caballero; Michael B Jordan; Omar Abdel-Wahab; Carl E Allen; Frédéric Charlotte; Eli L Diamond; R Maarten Egeler; Alain Fischer; Juana Gil Herrera; Jan-Inge Henter; Filip Janku; Miriam Merad; Jennifer Picarsic; Carlos Rodriguez-Galindo; Barret J Rollins; Abdellatif Tazi; Robert Vassallo; Lawrence M Weiss Journal: Blood Date: 2016-03-10 Impact factor: 22.113
Authors: Gaurav Goyal; Mithun V Shah; Timothy G Call; Mark R Litzow; William J Hogan; Ronald S Go Journal: JAMA Oncol Date: 2017-09-01 Impact factor: 31.777
Authors: K M Bond; J C Benson; J K Cutsforth-Gregory; D K Kim; F E Diehn; C M Carr Journal: AJNR Am J Neuroradiol Date: 2020-07-09 Impact factor: 3.825
Authors: Massimo Marano; Antonio Todisco; Francesco Motolese; Carlo Cosimo Quattrocchi; Anna Crescenzi; Giovanni Cirillo; Vincenzo Di Lazzaro Journal: Mov Disord Clin Pract Date: 2020-01-22
Authors: Rahul N Prasad; Peter J Kobalka; Haley K Perlow; Daniel M Prevedello; Dukagjin M Blakaj; Raju R Raval; Joshua D Palmer Journal: Radiat Oncol J Date: 2022-05-20
Authors: Ankush Bhatia; Vaios Hatzoglou; Gary Ulaner; Raajit Rampal; David M Hyman; Omar Abdel-Wahab; Benjamin H Durham; Ahmet Dogan; Neval Ozkaya; Mariko Yabe; Kseniya Petrova-Drus; Katherine S Panageas; Anne Reiner; Marc Rosenblum; Eli L Diamond Journal: Neuro Oncol Date: 2020-07-07 Impact factor: 12.300